CEL-SCI Corp. (CVM)
2.14
-0.60
(-21.90%)
USD |
NYAM |
Oct 07, 14:11
CEL-SCI EPS Diluted (Quarterly) : -0.4678 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.4678 |
| March 31, 2026 | -0.6716 |
| December 31, 2025 | -0.6823 |
| September 30, 2025 | -0.7611 |
| June 30, 2025 | -1.365 |
| March 31, 2025 | -0.0777 |
| December 31, 2024 | -3.248 |
| September 30, 2024 | -2.873 |
| June 30, 2024 | -0.127 |
| March 31, 2024 | -0.1393 |
| December 31, 2023 | -0.1384 |
| September 30, 2023 | -0.1624 |
| June 30, 2023 | -0.1891 |
| March 31, 2023 | -0.1914 |
| December 31, 2022 | -0.1847 |
| September 30, 2022 | -0.2094 |
| June 30, 2022 | -0.2299 |
| March 31, 2022 | -0.2278 |
| December 31, 2021 | -0.2039 |
| September 30, 2021 | -0.19 |
| June 30, 2021 | -0.2179 |
| March 31, 2021 | -0.2817 |
| December 31, 2020 | -0.2134 |
| September 30, 2020 | -0.1432 |
| June 30, 2020 | -0.2744 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.2507 |
| December 31, 2019 | -0.1577 |
| September 30, 2019 | -0.1376 |
| June 30, 2019 | -0.3656 |
| March 31, 2019 | -0.2215 |
| December 31, 2018 | 0.0174 |
| September 30, 2018 | -0.7049 |
| June 30, 2018 | -0.36 |
| March 31, 2018 | -9.286 |
| December 31, 2017 | -0.53 |
| September 30, 2017 | -16.00 |
| June 30, 2017 | -0.53 |
| March 31, 2017 | -1.15 |
| December 31, 2016 | 8.00 |
| September 30, 2016 | -0.186 |
| June 30, 2016 | -585.00 |
| March 31, 2016 | -56.10 |
| December 31, 2015 | 397.50 |
| September 30, 2015 | -75.00 |
| June 30, 2015 | -1.50 |
| March 31, 2015 | -4.25 |
| December 31, 2014 | -2.75 |
| September 30, 2014 | -2.732 |
| June 30, 2014 | -2.75 |
| March 31, 2014 | -6.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
| Imunon, Inc. | -0.5412 |
| Curis, Inc. | -4.017 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.668M |
| Total Expenses (Quarterly) | 5.668M |
| Enterprise Value | 49.56M |
| Earnings Yield | -120.7% |
| Normalized Earnings Yield | -120.75 |